ALX Oncology Holdings Inc. ( ALXO, Financials) saw its stock price fall 15.8% to $1.52 as of 2:32 p.m. GMT-5 on Thursday, despite announcing positive updated results from its ASPEN-06 Phase 2 clinical ...

Three-fourths of patients with unresectable gastroesophageal cancer converted to resectable and had clear margins after ...

In March 2023 Sanofi Aventis obtained U.S. FDA approval to use TAXOTERE® (docetaxel) Injection Concentrate against advanced stomach cancer treatment that includes gastroesophageal junction cancer. The ...

In a remarkable medical achievement, an 86-year-old man presented to Manipal Hospital Vijayawada with a long-standing history ...

The ASPEN-06 data will be featured in an oral presentation (Abstract #332) at the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) earlier the same day.

if the site is at the level of the esophagogastric junction, a laparotomy is preferable, and the stomach can be used to reinforce the repair. If the damage to the esophagus is too extensive to ...

Five-year data shows lasting benefit for patients with advanced gastroesophageal cancers treated with nivolumab and chemotherapy.

Astellas Pharma's zolbetuximab – currently leading an expanding pack of drugs targeting claudin 18.2 – has shown efficacy in the first of a pair of phase 3 trials of gastric or ...

Analysts at Precedence Research project that the global stomach cancer treatment market will grow ... compared to TRP alone in patients with HER2-positive gastric or gastroesophageal junction cancer ...

Analysts at Precedence Research project that the global stomach cancer treatment market will grow ... compared to TRP alone in patients with HER2-positive gastric or gastroesophageal junction cancer ...

Sacituzumab tirumotecan is under clinical development by Merck and currently in Phase III for Adenocarcinoma Of The Gastroesophageal Junction. According to GlobalData, Phase III drugs for ...